Skip to main content

Design of novel inhibitors of hcv rna helicase - potential antivirals for treatment and protection against hepatitis c virus-induced diseases (HCV INHIBITORS)

Objective

Hepatitis C virus (HCV) infections lead to liver cirrhosis and hepatocellular carcinoma. Currently no efficient drug or vaccine is available. A team of 6 European laboratories from D, F, PL will synthesise and investigate the psycho-chemical and biological properties of a broad range of new modified nucleoside derivatives, guanine, trampoline and anthracycline analogy and their prod rugs, potential inhibitors of HCV RNA helices, a novel and promising target for anti- HCV therapy. The interactions of analogy with HCV helices will be investigated with the use of kinetic methods, crystallography, and multidimensional NMR and CD spectroscopy. Inhibitory activity against HCV helices will be verified in vitro in HCV-infected human macrophages, in human hepatocytes and in yeast cell system. This research should deliver new anti-HCV drugs and may improve the quality of life of millions of HCV-infected patients.

Funding Scheme

CSC - Cost-sharing contracts

Coordinator

INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS - POLISH ACADEMY OF SCIENCES
Address
Pawinskiego 5A
02-106 Warszawa
Poland

Participants (5)

BERNHARD NOCHT INSTITUT FUER TROPENMEDIZIN
Germany
Address
Bernhard-nocht-strasse 74
Hamburg
FREIE UNIVERSITAET BERLIN
Germany
Address
Takustrasse 6
14195 Berlin
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Address
Cours Albert Thomas 151 Adr 5 - Rhône-alpes, Auve
69424 Lyon
INSTITUTE OF ORGANIC INDUSTRY
Poland
Address
Doswiadczalna 27
43 200 Pszczyna
INSTYTUT MEDYCYNY DOSWIADCZALNEJ I KLINICZNEJ POLSKIEJ AKADEMII NAUK
Poland
Address
Pawinskiego 5
02 106 Warszawa